Which MIGS device to use in a patient with glaucoma?
MIGS devices should be restricted to patients with mild to moderate glaucoma controlled by medication
Roibeard O’hEineachain
Published: Tuesday, February 21, 2017
In eyes where glaucoma is progressing despite maximal medication, trabeculectomy remains the best optionIn the early trials with first-generation iStents, 66% of eyes with the drainage implants compared achieved 20% IOP reduction, but also had a reduction in their requirement for IOP-lowering medications. In trials with ab interno MIGS devices which direct aqueous out to the subconjunctival space, like the XEN implant, the implants have achieved 30% to 40% IOP reductions in a high proportion of patients. The jury is still out regarding implants that direct aqueous to the suprachoroidal space. In general, MIGS devices should be restricted to patients with mild to moderate glaucoma controlled by medication. In eyes where glaucoma is progressing despite maximal medication, trabeculectomy remains the best option, he concluded.
Latest Articles
From Lab to Life: Corneal Repair Goes Cellular
Long-awaited cellular therapies for corneal endothelial disease enter the clinic.
Balancing Innovation and Safety
Ensuring access to advanced cell therapies amid regulatory overhaul.
With Eyes on Its Future, ESCRS Celebrates Its Past
Winter Meeting offers opportunities to experiment with new concepts and formats.
Best of ESCRS Winter Meeting 2024
Following the New Generation
EDOF IOLs an option for eyes with mild comorbidities, showing potential in mini-monovision strategies.
Refocus on Multifocals
Trifocal IOLs continue to improve as consensus grows regarding indications and contraindications.
Common Myths in Presbyopia Correction
Patient education key to satisfaction with refractive IOLs.
Reversible Multifocality
Two-lens combination offers low-risk spectacle independence for cataract patients and presbyopes.
Managing a Cataract Surgery Refractive Miss
Weighing the pros and cons of options for intraocular intervention.
Unleashing OCT’s Full Potential
Performance of newest tool for corneal evaluation meets or beats older standard technologies.